Scholarlink

Introduction <p>This work aims to evaluate the real-world efficacy and safety of intravitreal faricimab over a 6-month follow-up period.</p> Methods <p>Data from 38 centers across Turkey were retrospectively analyzed between November 22, 2024, and May 4, 2025. Patients who received at least one intravitreal faricimab injection and had complete ophthalmic and optical coherence tomography (OCT) data with a minimum 1-month follow-up were included. Demographics, diagnosis, macular neovascularization (MNV) subtype, prior treatments, best-corrected visual acuity (BCVA-decimal/ETDRS), central macular thickness (CMT), intra/subretinal fluid, MNV size, injection number, follow-up duration, and ocular/systemic adverse events were recorded at baseline, at week 2, and at month 1 after the first injection, after three injections, and at the final visit.</p> Results <p>A total of 351 eyes from 316 patients were analyzed, including neovascular age-related macular degeneration (nAMD) (72.1%), diabetic macular edema (DME) (18.2%), retinal vein occlusion (RVO) (6.0%), and other MNV subtypes (3.7%). When comparing pre-treatment and final visits, naïve eyes showed a CMT reduction of 105.63 ± 114.89&#xa0;µm (<i>p</i> &lt; 0.001), while switch eyes had a CMT reduction of 86.58 ± 108.36&#xa0;µm (<i>p</i> &lt; 0.001). The total ETDRS letter gain from baseline to final visit was 16.3 ± 12.08 (<i>p</i> &lt; 0.001) in naïve eyes and 8.3 ± 12.23 (<i>p</i> &lt; 0.001) in switch eyes. Intraretinal and subretinal fluid rates significantly decreased (<i>p</i> &lt; 0.001), and MNV area contracted on OCTA (<i>p</i> &lt; 0.001). Only one mild, self-limited intraocular inflammation case (0.16%) occurred.</p> Conclusions <p>Faricimab demonstrated rapid and significant anatomical and functional improvements in 6-month real-world data, evident as early as 15&#xa0;days after the initial injection, with a safety profile comparable to phase III trials. These findings support faricimab as a potent and reliable therapeutic option in the real-world management of nAMD and DME, though extended follow-up is needed to assess long-term outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World 6-Month Treatment Outcomes of Faricimab in Turkey: The FARTURK Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月25日

查看全文
  • Akın Çakır,
  • Fevzi Akkan,
  • Ziya Kapran,
  • Melih Ünal,
  • Nigar Şerif,
  • Tahsin Uzundede,
  • Gamze Karataş,
  • Mahmut Öztürk,
  • Hüseyin Dündar,
  • Tansu Erakgün,
  • Mehmet Numan Alp,
  • Nilüfer Koçak,
  • Ali Osman Saatci,
  • Ebru Nevin Çetin,
  • Ali Hakan Durukan,
  • Muzaffer Şahin,
  • Ferşat Muhacir,
  • Yağmur Seda Yeşiltaş,
  • Osman Murat Uyar,
  • Sinan Emre,
  • Mehmet Ali Şekeroğlu,
  • Mehmet Önen,
  • Mehmet Bulut,
  • Aylin Karalezli,
  • Sibel Kadayıfçılar,
  • Şengül Özdek,
  • Selim Doğanay,
  • Mahmut Kaya,
  • Özay Öz,
  • Sema Tamer Kaderli,
  • Remzi Avcı,
  • Figen Şermet,
  • Sibel Demirel,
  • Cem Küçükerdönmez,
  • Cem Yıldırım,
  • Şefik Can İpek,
  • Ziya Ayhan,
  • Tuğrul Altan,
  • İhsan Gökhan Gürelik,
  • Ebru Görgün,
  • Nursal Melda Yenerel,
  • Göktuğ Seymenoğlu,
  • Esra Vural,
  • Sabahattin Sül,
  • Mehmet Çıtırık,
  • Hüseyin Baran Özdemir,
  • Doğukan Cömerter,
  • Veysel Levent Karabaş,
  • Hakan Özdemir

摘要

Introduction

This work aims to evaluate the real-world efficacy and safety of intravitreal faricimab over a 6-month follow-up period.

Methods

Data from 38 centers across Turkey were retrospectively analyzed between November 22, 2024, and May 4, 2025. Patients who received at least one intravitreal faricimab injection and had complete ophthalmic and optical coherence tomography (OCT) data with a minimum 1-month follow-up were included. Demographics, diagnosis, macular neovascularization (MNV) subtype, prior treatments, best-corrected visual acuity (BCVA-decimal/ETDRS), central macular thickness (CMT), intra/subretinal fluid, MNV size, injection number, follow-up duration, and ocular/systemic adverse events were recorded at baseline, at week 2, and at month 1 after the first injection, after three injections, and at the final visit.

Results

A total of 351 eyes from 316 patients were analyzed, including neovascular age-related macular degeneration (nAMD) (72.1%), diabetic macular edema (DME) (18.2%), retinal vein occlusion (RVO) (6.0%), and other MNV subtypes (3.7%). When comparing pre-treatment and final visits, naïve eyes showed a CMT reduction of 105.63 ± 114.89 µm (p < 0.001), while switch eyes had a CMT reduction of 86.58 ± 108.36 µm (p < 0.001). The total ETDRS letter gain from baseline to final visit was 16.3 ± 12.08 (p < 0.001) in naïve eyes and 8.3 ± 12.23 (p < 0.001) in switch eyes. Intraretinal and subretinal fluid rates significantly decreased (p < 0.001), and MNV area contracted on OCTA (p < 0.001). Only one mild, self-limited intraocular inflammation case (0.16%) occurred.

Conclusions

Faricimab demonstrated rapid and significant anatomical and functional improvements in 6-month real-world data, evident as early as 15 days after the initial injection, with a safety profile comparable to phase III trials. These findings support faricimab as a potent and reliable therapeutic option in the real-world management of nAMD and DME, though extended follow-up is needed to assess long-term outcomes.